Comparative Pharmacology
Head-to-head clinical analysis: SULFADIAZINE versus SULSOXIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFADIAZINE versus SULSOXIN.
SULFADIAZINE vs SULSOXIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibitor of dihydropteroate synthase, blocking the synthesis of folic acid in bacteria.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs) and disrupting peptidoglycan cross-linking.
Oral: 2-4 g initially, then 1 g every 4-6 hours for mild to moderate infections; for severe infections, 4 g initially followed by 1.5 g every 4 hours. IV: Not available in IV form in the US; if using oral suspension, adjust accordingly.
500 mg orally 4 times daily for 10-14 days (or 1 g orally 4 times daily for severe infections).
None Documented
None Documented
Terminal elimination half-life 10-20 hours (prolonged in renal impairment; may require dose adjustment)
Clinical Note
moderateSulfadiazine + Gatifloxacin
"Sulfadiazine may increase the hypoglycemic activities of Gatifloxacin."
Clinical Note
moderateSulfadiazine + Rosoxacin
"Sulfadiazine may increase the hypoglycemic activities of Rosoxacin."
Clinical Note
moderateSulfadiazine + Levofloxacin
"Sulfadiazine may increase the hypoglycemic activities of Levofloxacin."
Clinical Note
moderateSulfadiazine + Trovafloxacin
"Sulfadiazine may increase the hypoglycemic activities of Trovafloxacin."
8 hours (terminal) — extends in renal impairment (up to 24 hours in CrCl <30 mL/min); requires dose adjustment
Renal excretion of unchanged drug (50-70%) and acetylated metabolites; minor biliary/fecal (<5%)
Renal: 70% (unchanged); biliary/fecal: 20%; minor hepatic metabolism (<10%)
Category D/X
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic